Global Opportunities Trust reaffirms successful value and absolute-return strategy (LON: GOT)

GOT

Global Opportunities Trust Plc (LON:GOT) has provided its monthly factsheet for October 2025.

Global Opportunities Trust reported total assets of £117.5 million at 31 October 2025, with a net asset value of 402.0p per share and a share price of 333.0p, representing a 17.2 per cent discount. The trust maintains a diversified mix of equity holdings and liquidity funds, with the top ten equity positions accounting for 36.1 per cent of net assets

Global Opportunities Trust plc LON:GOT) invests globally in undervalued asset classes without reference to the composition of any stock market index.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Global Opportunities Trust reports 1.5% NAV total return for first half of 2026

Global Opportunities Trust reported positive half-year returns, a wider discount to NAV, and provided an updated outlook and portfolio review.

AI valuations face a more demanding capital cycle

AI remains a powerful long-term theme, but rising capital needs, stronger competition and closer scrutiny are making valuation and execution increasingly important.

Global Opportunities Trust offers a distinctive route through elevated AI valuations

Global Opportunities Trust combines defensive stock selection, valuation discipline and a substantial cash position as markets assess the risks surrounding elevated AI-related valuations.

Unilever’s award-winning marketing supports its brand-led growth strategy

Unilever’s 2026 Cannes Lions campaigns show how the group is using consumer behaviour and local relevance to support its major brands.

Nestlé expands coffee capacity in Thailand with CHF563 million investment

Nestlé is investing CHF563 million in a new Nescafé production and distribution facility in Thailand, with operations expected to begin in 2028.

Sanofi builds long-term vaccine manufacturing position in Vietnam

Sanofi is strengthening its position in Vietnam through a vaccine technology-transfer project targeting local production from 2028.

Search